Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RADIUS HEALTH, INC.

(RDUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

10/20/2021 | 08:30am EST

the Menarini Group and Radius Health, Inc. announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC). There were two primary endpoints: progression-free survival (PFS) in the overall population and PFS in patients with tumors harboring estrogen receptor 1 (ESR1) mutations. EMERALD met both primary endpoints, showing statistically significant PFS in the overall population and ESR1 mutation subgroup. The safety profile of elacestrant exhibited in EMERALD was similar to that of the previous clinical trial. Given these results, Menarini and Radius plan on proceeding with regulatory submissions in both the United States and European Union in 2022. In 2018, elacestrant received fast track designation from the FDA. Elacestrant is a selective estrogen receptor degrader (SERD). It was being investigated in the Phase 3 EMERALD trial as a potential once daily, oral treatment, in patients with ER+/HER2- mBC. Overall, 466 patients were enrolled in the study, including 220 (47%) with tumors harboring an Estrogen Receptor 1 (ESR1) mutation. ESR1 mutations are important drivers for the development of resistance to endocrine therapy in ER+/HER2- mBC patients.


ę S&P Capital IQ 2021
All news about RADIUS HEALTH, INC.
11/15RADIUS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
11/15Radius Health, Inc. Announces Executive Changes
CI
11/11Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference
AQ
11/09HC Wainwright Adjusts Price Target on Radius Health to $23 From $26, Keeps Neutral Rati..
MT
11/08Radius Health Swings to Q3 Loss as Revenue Falls
MT
11/08RADIUS HEALTH, INC. : Third Quarter 2021 Results - Form 8-K
PU
11/08RADIUS HEALTH : Q3 Earnings Snapshot
AQ
11/08Earnings Flash (RDUS) RADIUS HEALTH Posts Q3 Loss $-0.32
MT
11/08Earnings Flash (RDUS) RADIUS HEALTH Posts Q3 Revenue $56.8M, vs. Street Est of $61.3M
MT
11/08RADIUS HEALTH, INC. : Third Quarter 2021 Results
AQ
More news
Analyst Recommendations on RADIUS HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 228 M - -
Net income 2021 -60,2 M - -
Net Debt 2021 170 M - -
P/E ratio 2021 -12,4x
Yield 2021 -
Capitalization 759 M 759 M -
EV / Sales 2021 4,07x
EV / Sales 2022 3,19x
Nbr of Employees 310
Free-Float 98,9%
Chart RADIUS HEALTH, INC.
Duration : Period :
Radius Health, Inc. Technical Analysis Chart | RDUS | US7504692077 | MarketScreener
Technical analysis trends RADIUS HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 16,03 $
Average target price 23,43 $
Spread / Average Target 46,2%
EPS Revisions
Managers and Directors
George Kelly Martin President, Chief Executive Officer & Director
Steven Helwig CFO, Treasurer & Chief Accounting Officer
Owen Patrick Hughes Chairman
Bruce Mitlak Chief Medical Officer
Averi Price Secretary, Chief Compliance Officer & VP
Sector and Competitors
1st jan.Capi. (M$)
RADIUS HEALTH, INC.-12.99%759
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.13%65 499
VERTEX PHARMACEUTICALS-13.49%51 982